Editorial on the Research Topic COVID-and hyper inflammation syndrome: Di erent presentation and management More than 2 years after the declaration of a pandemic for SARS-CoV-2 infection, COVID-19 is still a major public health, social and economic issue worldwide (1). Although children are less severely affected by SARS-CoV-2 infection than adults, during these years the impact of COVID-19 on the pediatric population has clearly emerged in all its facets, which were not entirely evident at the beginning of the pandemic (2, 3).Most clinical studies were carried out in developed countries, but pediatric COVID-19 represents a relevant problem even in developing countries, where performing well-designed clinical studies may be more difficult (4-6). The articles included in this Research Topic are from different continents (Europe, Asia, and America) and investigated several aspects of the clinical presentation, pathophysiological mechanisms, and medical management of SARS-CoV-2 infection in children.Through their case reports, Generalić et al., Emeršič et al., Artamonova et al., can also present with protean and unusual clinical manifestations in children.However, the most challenging clinical aspect of pediatric SARS-CoV-2 infection is represented by the multisystem inflammatory syndrome in children (MIS-C). In their article submitted in the first part of 2021, Matucci-Cerinic et al. analyzed MIS-C by comparing it with Kawasaki Disease (KD). They listed the main similarities and differences between these hyper-inflammatory disorders and hypothesized that MIS-C could be viewed as a disorder included in the KD spectrum, instead of representing aFrontiers in Pediatrics frontiersin.org